Latest Healthcare News

Vitura Health Limited has announced its third fully franked dividend of 0.2 cents per share following a profitable FY2025, reinforcing its unique position in the medicinal cannabis sector. Shareholders are invited to participate in a discounted Dividend Reinvestment Plan.

Vitura Health reported modest revenue growth but a robust 23.5% increase in EBITDA for FY2025, fueled by key acquisitions and expanding telehealth services. Despite margin pressures in medicinal cannabis, the company’s strategic reset under new leadership sets the stage for further growth.

Apiam Animal Health has entered a Process Deed granting Adamantem exclusivity to pursue a $0.88 per share acquisition proposal. The Independent Board Committee signals intent to recommend the deal, pending due diligence and shareholder approval.

Vitura Health reported a modest revenue increase to $124 million for FY2025, while net profit dipped 5.35% due to margin pressures and investment in new platforms. The company declared a fully franked dividend and highlighted growth in telehealth and medical services.

nib Holdings reported a solid FY25 with underlying operating profit of $239.2 million and 3.2% policyholder growth, driven by digital innovation and operational efficiencies. The Group’s strategic focus on core health insurance and adjacent services sets the stage for continued momentum into FY26.

nib Group reported solid FY25 results with revenue growth to $3.6 billion and a 9.4% rise in net profit after tax, while maintaining its full-year dividend at 29 cents per share. The company’s Australian private health insurance business achieved record policyholder growth amid ongoing claims inflation and operational efficiencies.

nib holdings limited reported a 9.4% increase in net profit after tax to $198.6 million for FY25, alongside a 7.8% rise in group revenue to $3.6 billion. Despite a dip in underlying operating profit, the company declared a fully franked final dividend, maintaining its full-year payout at 29 cents per share.

Vita Life Sciences delivered a robust first half in 2025 with record revenue and profit growth, driven by strong performances in Australia and Southeast Asia. The company also raised its interim dividend and expanded marketing efforts.

Vita Life Sciences reported a robust half-year performance with revenue up 15.4% to A$45.5 million and a 12.2% rise in net profit, driven by strong growth in Australia and Southeast Asia. The company also increased its interim dividend to 4.5 cents per share, signaling confidence despite challenges in China.

Ansell Limited reported record FY25 sales and EBIT margins, completing KBU integration ahead of schedule and upgrading synergy targets. The company guides higher adjusted EPS for FY26, fully offsetting US tariff hikes through pricing.

Ansell Limited has announced an unfranked ordinary dividend of USD 0.28 per share for the six months ending June 2025, accompanied by a Dividend Reinvestment Plan available to select shareholders.

Universal Biosensors Inc. has been suspended from ASX trading following the appointment of voluntary administrators, highlighting serious financial distress within the company.